Back to mobile site

Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX)

June 22, 2026 9:29 AM EDT Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $188.00 price target on Neurocrine Bio. (NASDAQ: NBIX).The analyst commented, "At ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login